Author

Linh Tran

Revolution Medicines (United States)ORCID 0009-0004-5279-3134Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Linh Tran1 paper · Hobart and William Smith Colleges

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:metagenomics· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Adrienne D. CoxiD· 1 shared Andrew M. WatersiD· 1 shared Bjoern PapkeiD· 1 shared Channing J. DeriD· 1 shared Christine SersiD· 1 shared Clint A. StalneckeriD· 1 shared Cole P MartiniD· 1 shared Craig M. GoodwiniD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adrienne D. CoxORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintAug 11, 2026

Concurrent AXL inhibition enhances RAS and ERK inhibitor efficacy in KRAS-mutant pancreatic and lung cancer

Yan Ming Ching, Shruthi Narayanan, Jeffrey A. Klomp…·Bjoern Papke

This study shows that combining AXL inhibition with RAS or ERK inhibitors enhances efficacy in KRAS-mutant cancers by overcoming resistance mechanisms.

1 citation

𝕏 PostBluesky